Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Incentive Legislation: Can Reimbursement Horn In?

This article was originally published in RPM Report

Executive Summary

There are two antibiotic incentive bills vying for attention in Congress. One is a follow-on to the popular GAIN Act; the other takes a new path – creating generous reimbursement formulas to help the next wave of anti-infectives find a successful niche in hospital market.

You may also be interested in...



Antibiotic Incentives Moving Forward: “Cures” Act Pathway May Apply More Broadly

Anti-infective drug development companies appear set to receive another round of legislative incentives as the “Cures” process moves forward. The only question is when and how much they will receive. One provision—creating a new limited use pathway—could be important for all classes of drug development.

Doubling Down On Antibiotic Incentives: Congress, Obama Administration Drafting Proposals

The 2012 FDA Safety & Innovation Act included important new incentives for antibiotic developers. But the Obama Administration and key legislators want to do even more to revive R&D in the space. What will it take to bring Big Pharma back?

2020 Antibiotic Goal in Jeopardy? HHS Analysis Shows Need For Earlier, Larger Incentives

Goal of 10 new antibiotics by 2020 may be unlikely given current marketplace for antibiotics, some experts predict as a new study shows recent proposals to revive development may be focused at wrong point in development timeline. Study suggests need for large increases in government funding.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS079717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel